NEW YORK, June 28, 2017 /PRNewswire/ --
According to a recent report by New Frontier Data, the Viridian Cannabis Stock Index gained 236.1% in 2016, or outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), the S&P 500 (up 9.5%), and the Nasdaq composite (up 7.5%). Businesses that touch the plant and in ancillary sector, helps to show the data growth in 2016 of underlying sectors in the cannabis markets. New Frontier Data also indicates that in 2017, medical cannabis sales are forecast to grow to $5.3 billion, or accounting for 67% of total cannabis sales. By 2025, medical sales in currently legal states are forecast to grow to $13.2 billion, at this point medical sales will account for 55% of all sales. Comparatively, adult-use sales in 2017 are forecast to reach $2.6 billion, or rising to $10.9 billion by 2025. ChineseInvestors.com, Inc. (OTC: CIIX), Cannabis Sativa, Inc. (OTC: CBDS), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeuticsis Inc. (NASDAQ: INSY), Cara Therapeutics Inc. (NASDAQ: CARA).
A major portion of the legal cannabis market is the Hemp and CBD market. Sean Murphy, the Founder and Publisher of Hemp Business Journal explained, "Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR."
ChineseInvestors.com, Inc. (OTCQB: CIIX) just announced earlier today that its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., will officially launch its first line of non-industrial hemp infused skin care products, the 'CBD Magic Hemp Series'. The product line will include four products, namely, CBDBIO TECH Toner, CBDBIO TECH Rejuvenating Cream, and CBDBIO TECH Perfecting Shield Primer and CBDBIO TECH Rejuvenating Spray.
The new skin care line is expected to be launched in this quarter of 2017. CBD Biotechnology Co. Ltd. plans to use multiple sales channels to implement its sales plan including Tmall, TaoBao, the Company's official website, broadcasting platforms of internet celebrities, mobile news applications, and a multi-level direct selling system in cooperation with Shangdong Yibao Biologics Co. Ltd.
"Following the launch of OptHemp Ultra Premium Hemp Oil by CIIX's wholly owned U.S. subsidiary, ChineseHempOil.com, Inc., I am very pleased to announce the launch of CBD Biotechnology Co., Ltd. non-industrial hemp infused skin care line," says Summer Yun, CEO of CBD Biotechnology Co., Ltd. "CBD Biotechnology Co., Ltd. will be one of the first companies in China to incorporate hemp-based CBD into skin care products, which we believe will spark public interest."
"An estimated 55,700 metric tons of industrial hemp are produced around the world each year with China, Russia, and South Korea leading in production, accounting for 70 percent of the world's industrial hemp supply. Although China is one of the leading producers of industrial hemp, the benefits to the human body have not yet been widely recognized in mainland China," says Yun. "As one of the companies to introduce a skin care line infused with hemp-based CBD to China, CIIX looks forward to educating the almost 1.4 billion people in China about the benefits of hemp-based CBD and the positive effects it can have on the largest, visible human organ - the skin."
On April 10, 2017, Cannabis Sativa, Inc. (OTCQB: CBDS) announced that it entered into an agreement to acquire the intellectual property for the White Rabbit brand of cannabis sprays and cannabis mints. The White Rabbit product line currently consists of fast acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each. The Company's President David Tobias stated, "The White Rabbit line of products is very attractive to us given its low dose and metering, which are important qualities for medicinal use."
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. The company recently announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.
Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys Therapeuticsis Inc. (NASDAQ: INSY) is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Earlier in May, the company announced that the U.S. Food and Drug Administration ('FDA') has approved the final product label for Syndros™ (dronabinol) oral solution, CII, a liquid formulation of the pharmaceutical cannabinoid, dronabinol. Syndros is approved for use in treating anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome ('AIDS') and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Cara's most advanced CB compound, CR701, is in preclinical development. Dr. Joseph Stauffer, CMO Cara Therapeutics, said, "Cannabinoid Receptor Agonists like CR701 have the potential to provide improved pain relief for patients suffering from neuropathic pain."
Please Sign Up Now at http://www.FinancialBuzz.com to receive alerts on trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE: https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: